Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin
- PMID: 9363868
- DOI: 10.1200/JCO.1997.15.11.3368
Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin
Abstract
Purpose: Thrombocytopenia may compromise cancer treatment, causing chemotherapy dose reductions, schedule alterations, or the need for platelet transfusions. We evaluated the efficacy and safety of recombinant human interleukin-11 (rhIL-11; Neumega, Genetics Institute, Inc, Cambridge, MA), a novel thrombopoietic growth factor, in reducing the need for platelet transfusions in patients who undergo dose-intensive chemotherapy.
Patients and methods: Women with advanced breast cancer received cyclophosphamide (3,200 mg/m2) and doxorubicin (75 mg/m2) plus granulocyte colony-stimulating factor (G-CSF; 5 microg/kg/d). Patients were randomized to blinded treatment with placebo or 50 microg/kg/d rhIL-11 subcutaneously for 10 or 17 days after the first two chemotherapy cycles.
Results: Seventy-seven patients were randomized and constitute the intent-to-treat (ITT) population. Sixty-seven patients (the assessable subgroup) either completed both cycles without a major protocol violation (n = 62) or received a platelet transfusion before treatment was discontinued after the first cycle. In the ITT population, rhIL-11 significantly decreased the requirement for platelet transfusions; 27 of 40 (68%) patients who received rhIL-11 did not require transfusions, compared with 15 of 37 (41%) in the placebo group (P = .04). Treatment with rhIL-11 significantly reduced the total number of platelet transfusions required in the assessable subgroup (P = .03) and the time to platelet recovery to more than 50,000/microL in the second cycle (P = .01). Most adverse events associated with rhIL-11 were reversible, mild to moderate in severity, and likely related to fluid retention.
Conclusion: rhIL-11 is safe and effective in reducing treatment-associated thrombocytopenia and the need for platelet transfusions in patients who undergo dose-intensive chemotherapy, and thus may permit chemotherapy to be administered as planned at intended doses and thereby maximize the potential for a successful outcome.
Similar articles
-
[Effectiveness and safety of recombinant human interleukin-11 in the treatment of chemotherapy-induced thrombocytopenia].Zhonghua Zhong Liu Za Zhi. 2006 Jul;28(7):542-4. Zhonghua Zhong Liu Za Zhi. 2006. PMID: 17147124 Clinical Trial. Chinese.
-
[Phase II clinical trial on China manufactured recombinant human interleukin-11 derivative in the prevention and treatment of chemotherapy-induced thrombocytopenia].Zhonghua Zhong Liu Za Zhi. 2005 Jun;27(6):373-6. Zhonghua Zhong Liu Za Zhi. 2005. PMID: 16117903 Clinical Trial. Chinese.
-
Clinical efficacy of rhIL-11.Oncology (Williston Park). 2000 Sep;14(9 Suppl 8):32-40. Oncology (Williston Park). 2000. PMID: 11033836 Clinical Trial.
-
Dose reductions and delays: limitations of myelosuppressive chemotherapy.Oncology (Williston Park). 2000 Sep;14(9 Suppl 8):21-31. Oncology (Williston Park). 2000. PMID: 11033835 Review.
-
The clinical development of recombinant human interleukin 11 (NEUMEGA rhIL-11 growth factor).Stem Cells. 1996;14 Suppl 1:256-60. doi: 10.1002/stem.5530140733. Stem Cells. 1996. PMID: 11012229 Review.
Cited by
-
Understanding interleukin 11 as a disease gene and therapeutic target.Biochem J. 2023 Dec 13;480(23):1987-2008. doi: 10.1042/BCJ20220160. Biochem J. 2023. PMID: 38054591 Free PMC article. Review.
-
Interleukin-11 and its eminent role in tissue fibrosis: a possible therapeutic target.Clin Exp Immunol. 2023 Dec 12;214(2):154-161. doi: 10.1093/cei/uxad108. Clin Exp Immunol. 2023. PMID: 37724596 Review.
-
Interleukin 11 (IL-11): Role(s) in Breast Cancer Bone Metastases.Biomedicines. 2021 Jun 8;9(6):659. doi: 10.3390/biomedicines9060659. Biomedicines. 2021. PMID: 34201209 Free PMC article. Review.
-
Ameliorative Effects of Osthole on Experimental Renal Fibrosis in vivo and in vitro by Inhibiting IL-11/ERK1/2 Signaling.Front Pharmacol. 2021 May 13;12:646331. doi: 10.3389/fphar.2021.646331. eCollection 2021. Front Pharmacol. 2021. PMID: 34054526 Free PMC article.
-
Determinants and Functions of CAFs Secretome During Cancer Progression and Therapy.Front Cell Dev Biol. 2021 Jan 22;8:621070. doi: 10.3389/fcell.2020.621070. eCollection 2020. Front Cell Dev Biol. 2021. PMID: 33553157 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical